从阿尔茨海默氏症的Aβ中产生的脂质诱导的凝结物形成触发了粉样蛋白聚合
Greta Šneiderienė1, Alicia González Díaz1, Sourav Das Adhikari2
1Yusuf Hamied Department of Chemistry, Centre for Misfolding Diseases, University of Cambridge, Cambridge CB2 1EW, United Kingdom.
概括
阿尔茨海默氏病涉及粉样β (Aβ) 聚合. 我们发现Aβ在脂质双层上形成凝结物,加速初始斑块形成并揭示早期疾病机制.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默病的发病与中枢神经系统中的粉样β (Aβ) 聚合有关.
- 目前的疗法针对的是Aβ聚合物形成的后期阶段,但早期的分子触发因素仍然不清楚.
研究的目的:
- 为了研究粉样β聚合的早期分子步骤.
- 为了确定粉样β是否可以形成影响核形成的结构.
主要方法:
- 利用分子测试和活细胞成像来观察粉样β在脂质双层上的行为.
- 分析了粉样β结构的组成和物理特性.
主要成果:
- 证明了粉样β酸在脂质双层上形成生物分子凝结物.
- 显示这些凝结物显著加快了粉样蛋白聚合的初级核化.
- 确认的凝结物含有脂和从液体过渡到固体,形成纤维.
结论:
- 揭露了粉样β的液体-液体相分离行为.
- 确定了粉样β聚合级联中的关键早期分子步骤.
- 提供了关于阿尔茨海默病病理学的启动的新见解.
相关概念视频
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160


